1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Tevogen received written notice from Nasdaq on September 29, 2026, confirming it regained compliance with the $50 million minimum market value of listed securities requirement for continued listing on the Nasdaq Global Market. With this and a prior September 9, 2026 notice on publicly held shares, both Nasdaq compliance matters are now closed, removing the listing deficiency concerns the company had previously disclosed.
Nasdaq notice dated September 29, 2026 confirmed compliance with the $50 million minimum market value of listed securities requirement (Rule 5450(b)(2)(A))
Earlier notice dated September 9, 2026 confirmed compliance with the minimum market value of publicly held shares requirement (Rules 5450(b)(2)(C) and 5450(b)(3)(C))
Company issued a press release on September 30, 2026, furnished as Exhibit 99.1
Outlook Therapeutics received a Nasdaq notice on September 25, 2026, stating its stock closed below $1.00 for 30 consecutive business days. The notice has no immediate effect on the listing, but the company has until March 24, 2027 to regain compliance, which requires a closing bid of at least $1.00 for ten consecutive business days.
Nasdaq notice dated September 25, 2026 cites a closing bid below $1.00 for 30 consecutive business days under Listing Rule 5550(a)(2)
Compliance Date is March 24, 2027, 180 calendar days under Rule 5810(c)(3)(A)
Company may be eligible for a second 180-day period and may need a reverse stock split; if not compliant, Nasdaq would issue a delisting notice that the company could appeal
BioMarin entered into a Settlement and License Agreement with Ascendis Pharma on September 24, 2026, replacing an August 2026 binding term sheet. Ascendis receives a non-exclusive license to BioMarin patents covering TransCon CNP (navepegritide, Yuviwel), and BioMarin receives royalties on net sales until May 2030. The filing says the parties will dismiss all pending litigation between them over the patents, and it does not disclose dollar amounts.
Agreement dated September 24, 2026, deemed effective August 28, 2026, and supersedes the term sheet reported on August 31, 2026
Royalty of 20% of annual net sales in the United States and 18% in the EU, Brazil and South Korea, until May 2030
Pending litigation between the parties relating to the BioMarin patent rights to be dismissed with prejudice
Ascendis agreed not to challenge BioMarin's patent rights; no dollar figures disclosed
MoonLake Immunotherapeutics said it submitted a Biologics License Application to the U.S. Food and Drug Administration on September 30, 2026, seeking approval of its tri-specific nanobody sonelokimab for moderate-to-severe hidradenitis suppurativa in adults and patients 12 years and older. The filing marks a regulatory step toward a possible approval, but the FDA has not yet decided whether to accept the application for review.
BLA submitted to the FDA on September 30, 2026 for sonelokimab in moderate-to-severe hidradenitis suppurativa
FDA acceptance decision expected within approximately 60 days of submission
Planned review timeline expected from the FDA within approximately 74 days of submission
ChargePoint entered a settlement term sheet on September 28, 2026 to resolve the Farooq Khan securities class action in federal court in Northern District of California. The company will pay a $11 million cash settlement, which requires Court approval, and the company denies any wrongdoing.
Cash settlement payment of $11,000,000, to be placed in escrow within 21 days after the later of preliminary Court approval or receipt of payment instructions
Company expects to sign a final Settlement Agreement and seek preliminary approval within 30 calendar days of signing the term sheet
Settlement would resolve claims against the company and former CEO Pasquale Romano, former CFO Rex Jackson, and former Chief Commercial and Revenue Officer Michael Hughes, if approved
All In FutureTech Alliance disclosed that counsel for stockholder Primo Vital Limited sent letters in May and September 2026 claiming that its prior beneficial ownership disclosures about director Jingsheng (Jason) Lu were inaccurate. The company says it takes no position on the dispute over 11,986,523 shares it reported as roughly 31.3% of its common stock, and that this report does not resolve who controlled those shares.
Primo Letters dated May 22, 2026 and September 2, 2026 claim Mr. Lu was removed as Primo's director on May 19, 2026 and lost authority on March 3, 2026, when Ourgame was placed into liquidation in the Cayman Islands.
The company's Form 10-K and Special Meeting Proxy Statement reported Primo as record holder of 11,986,523 shares, about 31.3% of common stock, with shared voting power held by Mr. Lu.
The company relied on a December 11, 2024 joint Schedule 13D/A and says it will evaluate further information and its disclosure obligations.
AEON Biopharma received official minutes from its FDA Type 2b meeting on the development path for ABP-450, a proposed biosimilar to BOTOX. The FDA agreed in principle with the company's two-stage pharmacodynamic study design and said previously completed Daewoong comparative studies may be submitted as supportive evidence, while the company will not start a standalone comparative efficacy study for now. The filing also says the Two-Year Milestone Warrants will expire on November 16, 2026, which affects warrant holders.
FDA agreed in principle with the two-stage CMAP pharmacodynamic study design; company expects to file an IND in Q4 2026 and start the study in Q1 2027
Previously completed Daewoong comparative studies may be considered as supportive evidence, subject to scientific bridging
No standalone comparative efficacy study planned at this time; company plans to return to the FDA in 2027
Two-Year Milestone Warrants will expire on November 16, 2026, unless exercised before that date
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.